Barclays’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Barclays’s Portfolio EFTR Stock Details EFTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-100	Closed	-$4	–	5593
2024 Q3	$4	Hold	100	–	–	﹤0.01%	5255
2024 Q2	$29	Buy	+100	New	+$237	﹤0.01%	4774
2023 Q4	–	Sell	-3	Closed	-$49	–	5395
2023 Q3	$49	Buy	+3	New	+$52	﹤0.01%	4557

Barclays's EFTR Position: Q4 2024 in Review

Barclays sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q4 2024, closing a stake of 100 shares — an estimated $4 sold.

Barclays first reported a position in EFTR in Q3 2023 and held it in 3 quarters. The position peaked at $49 in Q3 2023. 0 funds tracked by Wall St. Rank hold EFTR as of Q4 2024.

Barclays reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Barclays sold 100 eFFECTOR Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $4.
Barclays first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q3 2023 and held it in 3 quarters.
Barclays's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $49 in Q3 2023.
0 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Barclays's 13F filing for Q4 2024, filed 13 Feb 2025.